{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:23:55Z","timestamp":1761488635575},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8_supplement_3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2011,2,22]]},"DOI":"10.1212\/wnl.0b013e31820db40f","type":"journal-article","created":{"date-parts":[[2011,2,21]],"date-time":"2011-02-21T21:53:19Z","timestamp":1298325199000},"source":"Crossref","is-referenced-by-count":22,"title":["Future clinical challenges in multiple sclerosis"],"prefix":"10.1212","volume":"76","author":[{"given":"Reinhard","family":"Hohlfeld","sequence":"first","affiliation":[{"name":"From the Institute for Clinical Neuroimmunology (R.H.), Munich, Germany; and Image Analysis Center (F.B.) and Department of Neurology (C.P.), VU University Medical Center, Amsterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"From the Institute for Clinical Neuroimmunology (R.H.), Munich, Germany; and Image Analysis Center (F.B.) and Department of Neurology (C.P.), VU University Medical Center, Amsterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Polman","sequence":"additional","affiliation":[{"name":"From the Institute for Clinical Neuroimmunology (R.H.), Munich, Germany; and Image Analysis Center (F.B.) and Department of Neurology (C.P.), VU University Medical Center, Amsterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2010.01.002"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.2.169"},{"key":"e_1_3_5_4_2","first-page":"CD004678","article-title":"Glatiramer acetate for multiple sclerosis","volume":"5","author":"La Mantia L","year":"2010","unstructured":"La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2010;5:CD004678","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_5_2","first-page":"CD002002","article-title":"Interferon in relapsing-remitting multiple sclerosis.","author":"Rice GP","year":"2001","unstructured":"Rice GP, Incorvaia B, Munari L, et al.. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001:CD002002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000078885.05053.7D"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S8230"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70103-4"},{"key":"e_1_3_5_9_2","first-page":"79","article-title":"The effects of disease-modifying therapies on self-reported health utilities in multiple sclerosis","volume":"72","author":"Smith K","year":"2009","unstructured":"Smith K, Trisolini M, Eckert B, Vollmer T. The effects of disease-modifying therapies on self-reported health utilities in multiple sclerosis. Neurology 2009;72:A79","journal-title":"Neurology"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000320512.21919.d2"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70028-4"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907839"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-009-0272-3"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf252"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00451.x"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181cbf825"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.76"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.091234"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.30.051606.094313"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq206"},{"key":"e_1_3_5_22_2","first-page":"S78","article-title":"Preclinical evaluation of a selective sphingosine 1-phosphate receptor-1 modulator: in vitro binding selectivity and effects on experimental autoimmune encephalomyelitis in rats","volume":"15","author":"Shimozato T","year":"2009","unstructured":"Shimozato T, Tomisato W, Doi H, et al.. Preclinical evaluation of a selective sphingosine 1-phosphate receptor-1 modulator: in vitro binding selectivity and effects on experimental autoimmune encephalomyelitis in rats. Mult Scler 2009;15:S78","journal-title":"Mult Scler"},{"key":"e_1_3_5_23_2","first-page":"S126","article-title":"The S1P1\/S1P5 receptor modulator BAF312 reverses neurological deficits in ongoing EAE, reduces specific lymphocyte subsets in healthy volunteers and is a potential new multiple sclerosis therapy","volume":"15","author":"Nuesslein-Hildesheim B","year":"2009","unstructured":"Nuesslein-Hildesheim B, Gergely P, Wallstrom E, et al.. The S1P1\/S1P5 receptor modulator BAF312 reverses neurological deficits in ongoing EAE, reduces specific lymphocyte subsets in healthy volunteers and is a potential new multiple sclerosis therapy. Mult Scler 2009;15:S126","journal-title":"Mult Scler"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2009.41"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000344417.42972.54"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70349-0"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000316810.01120.05"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d7d651"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70168-X"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510361358"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2010.04.052"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn190"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2110"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp228"},{"key":"e_1_3_5_35_2","first-page":"S143","article-title":"Clinical outcomes in subgroups of patients treated with fingolimod (FTY720) or placebo: 24-month results from FREEDOMS","volume":"16","author":"von Rosenstiel P","year":"2010","unstructured":"von Rosenstiel P, Hohlfeld R, Calabresi P, et al.. Clinical outcomes in subgroups of patients treated with fingolimod (FTY720) or placebo: 24-month results from FREEDOMS. Mult Scler 2010;16:S143","journal-title":"Mult Scler"},{"key":"e_1_3_5_36_2","first-page":"S289","article-title":"Efficacy and safety of fingolimod in patients switched from intramuscular interferon beta-1a: results from the TRANSFORMS extension study","volume":"16","author":"Cohen J","year":"2010","unstructured":"Cohen J, Montalban X, Pelletier J, et al.. Efficacy and safety of fingolimod in patients switched from intramuscular interferon beta-1a: results from the TRANSFORMS extension study. Mult Scler 2010;16:S289","journal-title":"Mult Scler"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1ae0"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3248"},{"key":"e_1_3_5_39_2","unstructured":"Gilenya product information . Available at: http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gilenya.pdf. Accessed December 2010"},{"key":"e_1_3_5_40_2","first-page":"S135","article-title":"Effects of fingolimod on antibody response following steady state dosing in healthy volunteers: a 4-week, randomized, placebo-controlled study","volume":"16","author":"Schmouder R","year":"2010","unstructured":"Schmouder R, Boulton C, Wang N, David OJ. Effects of fingolimod on antibody response following steady state dosing in healthy volunteers: a 4-week, randomized, placebo-controlled study. Mult Scler 2010;16:S135","journal-title":"Mult Scler"},{"key":"e_1_3_5_41_2","first-page":"S146","article-title":"Lymphocytes and fingolimod: temporal pattern and relationship with infections","volume":"16","author":"Francis G","year":"2010","unstructured":"Francis G, Kappos L, O'Connor P, et al.. Lymphocytes and fingolimod: temporal pattern and relationship with infections. Mult Scler 2010;16:S146","journal-title":"Mult Scler"},{"key":"e_1_3_5_42_2","unstructured":"FDA Peripheral and CNS Advisory Committee Meeting Slides . Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee\/UCM216556.pdf. Accessed July 16 2010."},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq176"},{"key":"e_1_3_5_44_2","first-page":"1786","article-title":"Alemtuzumab vs","volume":"359","author":"Coles AJ","year":"2008","unstructured":"Coles AJ, Compston DA, Selmaj KW, et al.. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786\u20131801","journal-title":"interferon beta-1a in early multiple sclerosis. N Engl J Med"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.0b013e31820db40f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T13:48:38Z","timestamp":1711633718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0b013e31820db40f"}},"subtitle":["Relevance to sphingosine 1-phosphate receptor modulator therapy"],"short-title":[],"issued":{"date-parts":[[2011,2,22]]},"references-count":44,"journal-issue":{"issue":"8_supplement_3","published-print":{"date-parts":[[2011,2,22]]}},"alternative-id":["10.1212\/WNL.0b013e31820db40f"],"URL":"https:\/\/doi.org\/10.1212\/wnl.0b013e31820db40f","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,22]]}}}